Overall survival analysis showed that ccRCC patients with high RNASET2 expression levels had survival times that were significantly shorter than those ccRCC patients with lower RNASET2 expression levels (Fig. 1D). The gene discussed is RNASET2; the disease is nonpapillary renal cell carcinoma.